In response to arterial injury, vascular smooth muscle cells (VSMC) proliferate and migrate from the media to transform the intima from essentially a single layer of endothelial cells to a multilayered neointima that subsequently compromises the vascular lumen. Neointimal proliferation plays a critical role in the pathogenesis of atherosclerosis and restenosis after balloon angioplasty and arterial stenting. The fibrinolytic system is activated by vascular injury and plays a major role in modulating the ensuing vascular response. This application will focus on the interconnected functions of plasminogen activator inhibitor-1 (PAl-l), vitronectin, and fibrin(ogen), key components of the fibrinolytic system that appear to play major roles in regulating VSMC function, but whose in vivo actions during neointima development are poorly defined.
The Specific Aims of our studies are as follows:
Aim 1 : Test the hypothesis that PAl-1 mediates the proliferative response to vascular injury by fibrin(ogen)-dependent and fibrin(ogen)-independent pathways.
Aim 2. Test the hypothesis that PAI-1-RR (a mutant that lacks anti-proteolytic activity, binds vitronectin normally) can inhibit the pathologic vascular actions of PAl-1 by a dominant negative mechanism.
Aim 3. Test the hypothesis that vitronectin modulates the interactions of VSMC with fibrin matrices. We anticipate that these studies will greatly enhance our understanding of the role of the fibrinolytic system in the pathogenesis of neointima formation, and that they may lead to new strategies for treating or preventing this important clinical problem.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Program Projects (P01)
Project #
5P01HL057346-10
Application #
7476419
Study Section
Heart, Lung, and Blood Initial Review Group (HLBP)
Project Start
Project End
Budget Start
2007-08-01
Budget End
2008-07-31
Support Year
10
Fiscal Year
2007
Total Cost
$402,951
Indirect Cost
Name
University of Michigan Ann Arbor
Department
Type
DUNS #
073133571
City
Ann Arbor
State
MI
Country
United States
Zip Code
48109
Tomberg, Kärt; Westrick, Randal J; Kotnik, Emilee N et al. (2018) Whole exome sequencing of ENU-induced thrombosis modifier mutations in the mouse. PLoS Genet 14:e1007658
Khoriaty, Rami; Hesketh, Geoffrey G; Bernard, Amélie et al. (2018) Functions of the COPII gene paralogs SEC23A and SEC23B are interchangeable in vivo. Proc Natl Acad Sci U S A 115:E7748-E7757
Nie, Chao; Wang, Huimin; Wang, Rui et al. (2018) Dimeric sorting code for concentrative cargo selection by the COPII coat. Proc Natl Acad Sci U S A 115:E3155-E3162
Ji, Y; Adeola, O; Strawn, T L et al. (2017) Recombinant soluble apyrase APT102 inhibits thrombosis and intimal hyperplasia in vein grafts without adversely affecting hemostasis or re-endothelialization. J Thromb Haemost 15:814-825
Westrick, Randal J; Tomberg, Kärt; Siebert, Amy E et al. (2017) Sensitized mutagenesis screen in Factor V Leiden mice identifies thrombosis suppressor loci. Proc Natl Acad Sci U S A 114:9659-9664
Khoriaty, Rami; Vogel, Nancy; Hoenerhoff, Mark J et al. (2017) SEC23B is required for pancreatic acinar cell function in adult mice. Mol Biol Cell 28:2146-2154
Ji, Yan; Weng, Zhen; Fish, Philip et al. (2016) Pharmacological Targeting of Plasminogen Activator Inhibitor-1 Decreases Vascular Smooth Muscle Cell Migration and Neointima Formation. Arterioscler Thromb Vasc Biol 36:2167-2175
Khoriaty, Rami; Everett, Lesley; Chase, Jennifer et al. (2016) Pancreatic SEC23B deficiency is sufficient to explain the perinatal lethality of germline SEC23B deficiency in mice. Sci Rep 6:27802
Khoobchandani, Menka; Katti, Kavita; Maxwell, Adam et al. (2016) Laminin Receptor-Avid Nanotherapeutic EGCg-AuNPs as a Potential Alternative Therapeutic Approach to Prevent Restenosis. Int J Mol Sci 17:316
Xu, Xianjin; Ma, Zhiwei; Sun, Hongmin et al. (2016) SM-TF: A structural database of small molecule-transcription factor complexes. J Comput Chem 37:1559-64

Showing the most recent 10 out of 187 publications